Practice question

SH-SY5Y is thrice cloned subline of SK-N-SH neuroblastoma isolated from bone marrow metastasis of 4-year-old patient in 1970. Neuroblast-like phenotype maintains ability to proliferate rapidly in undifferentiated state and differentiate upon exposure to retinoic acid, phorbol 12-myristate 13-acetate, or brain-derived neurotrophic factor into neuron-like cells extending neurites, expressing mature neuronal markers microtubule-associated protein MAP2, tau, synaptophysin, neuron specific enolase, and catecholaminergic enzymes tyrosine hydroxylase and dopamine beta-hydroxylase. This plasticity makes SH-SY5Y cornerstone for neurobiology investigations of Parkinson disease modeled by neurotoxins MPP+ derived from MPTP, 6-hydroxydopamine, and rotenone inhibiting complex I producing dopamine neuron loss, Alzheimer studies involving amyloid beta induced toxicity and tau phosphorylation, electrophysiology of voltage-gated sodium and calcium channels, and neurite outgrowth assays. Unlike immunological lines such as Jurkat or hepatic HepG2, SH-SY5Y provides human neuronal background, albeit tumor-derived with residual proliferative capacity requiring differentiation for post-mitotic modeling. Induced pluripotent stem cell derived neurons now complement SH-SY5Y providing more physiological maturity. This knowledge strengthens laboratory safety, protocol reproducibility, and regulatory compliance critical for translational research and clinical applications, ensuring reliable data and workforce protection.